Table 1.
Clinical features
| Healthy (n = 15) |
Smokers (n = 15) |
COPD (n = 22) |
|
|---|---|---|---|
| Age, yr. (mean (SD) | 66 ± 4 | 65 ± 9 | 67.5 ± 8 |
| Sex (M/F) | 11/4 | 12/3 | 17/5 |
| Tobacco consumption, pack-yr | 0 | 24.1 ± 6 | 30.5 ± 8 |
| FEV1, % pred | 98 ± 3 | 89 ± 6 | 48.6 ± 8* |
| FVC, % pred | 91 ± 2 | 90 ± 4 | 91.5 ± 6 |
| FEV1/FVC % | 94 ± 5 | 88 ± 1 | 61.2 ± 10* |
| GOLD 1 (mild) patients, no. | 0 | 0 | 0 |
| GOLD 2 (moderate) patients, no. | 0 | 0 | 3 |
| GOLD 3 (severe) patients, no. | 0 | 0 | 19 |
| GOLD 4 (very severe) patients, no. | 0 | 0 | 0 |
| Receiving inhaled steroids, no. | 0 | 0 | 22 |
| Receiving theophyllines, no. | 0 | 0 | 0 |
| Receiving long-acting b2-agonist, no. | 0 | 0 | 22 |
| Receiving anticholinergics, no. | 0 | 0 | 22 |
| Total peripheral blood neutrophils | 4.2 ± 0.6 × 109/L | 6.5 ± 0.9 × 109/L* | 9.5 ± 2.1 × 109/L* |
COPD Chronic obstructive pulmonary disease, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity; Pack-yr = 1 year smoking 20 cigarettes-day. % pred, % predicted. Data are mean ± SDs. * P < 0.05 related to Healthy subjects